Monday, January 13, 2014 4:43:31 PM
Obviously, the addition of Dr Pierce has instilled additional confidence for me in ONCS.
Sure it's been mentioned, But it shouldn't be stressed enough the fact that management has chosen to bypass a R/S. This indicates the confidence that management has on the catalysts / pending data. In addition, I don't see what I would call PR fluff that many biotech stocks use to "pump" the stock to make up for deficiencies.
Look forward to the catalysts. It's really hard to believe how undervalued this company is when after seeing how disruptive this technology is. I don't see safety really being one of the issues with the FDA process...
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors • Nov 19, 2024 8:45 AM
FEATURED Greenlane Signs New U.S. Distribution Agreement with Veriteque USA, Manufacturer of the SwabTek™ and Verifique™ Brand of Field Test Kits • Nov 19, 2024 8:34 AM
Geo-Political Tensions and Trump's Increasing Military Budgets Could Boost Demand for Actelis' Cyber Hardened Networking Tech ($ASNS) • ASNS • Nov 19, 2024 10:24 AM
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary • CBDL • Nov 19, 2024 8:00 AM
Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • STKH • Nov 18, 2024 11:56 AM
North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • NBRI • Nov 18, 2024 9:00 AM